DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Harbor Investment Advisory LLC

Harbor Investment Advisory LLC reduced its holdings in DexCom, Inc. (NASDAQ:DXCM) by 30.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 464 shares of the medical device company’s stock after selling 200 shares during the quarter. Harbor Investment Advisory LLC’s holdings in DexCom were worth $36,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in DXCM. Versant Capital Management Inc acquired a new stake in DexCom in the 4th quarter valued at approximately $25,000. Riverview Trust Co increased its position in DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares during the period. RPg Family Wealth Advisory LLC acquired a new stake in DexCom in the 3rd quarter valued at approximately $57,000. Covestor Ltd increased its position in DexCom by 53.7% in the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after acquiring an additional 335 shares during the period. Finally, MassMutual Private Wealth & Trust FSB increased its position in DexCom by 46.7% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after acquiring an additional 265 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently commented on DXCM shares. Raymond James lowered their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Citigroup lifted their price target on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. JPMorgan Chase & Co. lifted their price target on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Finally, Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Five research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $99.29.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.30% of the stock is currently owned by insiders.

DexCom Stock Performance

Shares of DexCom stock opened at $87.09 on Thursday. The stock has a market cap of $34.02 billion, a PE ratio of 52.15, a price-to-earnings-growth ratio of 2.21 and a beta of 1.12. The business has a fifty day simple moving average of $78.70 and a 200-day simple moving average of $77.37. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.